Partial
Partially Aligned
Patient Risk:
Low
Summary
Two claims align with the provided label excerpts (drug identity as insulin aspart; indication to improve glycemic control). The remaining two claims are not supported by the provided FDA label sections, and one claim is only partially supported because the label excerpt does not explicitly state “faster-acting.”
Category Scores
Accurate Statements
Fiasp is used to improve blood sugar control in people with diabetes.
Supported by 1 INDICATIONS AND USAGE: "FIASP is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus."
Unsupported Statements
Searching "Fiasp June 2024" usually points to a regulatory update, a pricing/availability change, a patent/litigation milestone, or a new clinical/publication date around that month.
No information in the provided label sections about search queries, timelines (e.g., June 2024), or typical outcomes of searching for FIASP updates.
DrugPatentWatch.com provides patent/exclusivity tracking for Fiasp (insulin aspart).
No information in the provided label sections mentioning DrugPatentWatch.com, patent tracking, or exclusivity tracking.
Contradictions
Important Omissions
The label excerpt provided does not explicitly support the characterization "faster-acting" for Fiasp; it only establishes that FIASP contains insulin aspart (11 DESCRIPTION).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only clinically relevant claims evaluated are identity/indication. No dosing, contraindications, boxed warnings, or administration instructions are claimed in the provided responses; therefore, no direct safety-critical misstatement is evident from the listed claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Two claims are not supported by the provided FDA label sections, and one claim is only partially supported because “faster-acting” is not explicitly stated in the excerpt.
Suggested Improvement
Limit label-supported claims to those explicitly present in the provided sections (e.g., insulin aspart identity and indicated use for glycemic control). Remove or rephrase claims about search outcomes and DrugPatentWatch.com unless supported by appropriate labeled or regulatory documentation.